442199-19-1

Basic information

• Product Name: 4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78
• Synonyms: 4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78;tert-Butyl 4-((6-chloropyriMidin-4-yl)oxy)piperidine-1-carboxylate;4-(6-Chloro-pyrimidin-4-yloxy)-piperidine-1-Carbocylic acid tert-butyl ester
• CAS NO: 442199-19-1
• Molecular Formula: C₁₄H₂₀ClN₃O₃
• Molecular Weight: 313.7799
• Mol File: 442199-19-1.mol

Chemical Properties

• Appearance: /
• Density: 1.242
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78(442199-19-1)
• EPA Substance Registry System: 4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78(442199-19-1)

Safety Data

• Hazardous Substances Data: 442199-19-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78 is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a versatile building block in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78 is utilized as a precursor in the production of pesticides. Its chemical properties allow for the creation of effective pest control agents, contributing to improved crop protection and yield.
Used in Research and Development:
4-(6-Chloro-pyriMidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C14H20ClN3O3, MW: 313.78 is also employed in research and development settings. Its high purity and solid-state form make it suitable for use in various experimental procedures, including the synthesis of new compounds, testing of chemical reactions, and the investigation of its potential applications in different fields.

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 442198-65-4 (2E)-3-(4-Chlorophenyl)-N-[(1S)-2-[(2-{4-[(6-chloro-4-pyrimidinyl)oxy]-1-piperidinyl}-2-oxoethyl)amino]-2-oxo-1-(2-pyridylmethyl)ethyl]-2-propenamide 
• 1233199-27-3 C₂₃H₂₉FN₄O₅S 
• 1233199-36-4 C₂₃H₂₈FN₃O₆S 
• 1185314-18-4 4-chloro-6-(piperidin-4-yloxy)pyrimidine dihydrochloride 
• 691400-74-5 tert-butyl 4-(6-aminopyrimidin-4-yloxy)piperidine-1-carboxylate 
• 1259510-62-7 4-[6-(5-methanesulfonyl-2,3-dihydro-indol-1-yl)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid 1-(2-fluoro-benzyl)-pyrrolidin-3-yl ester 

Relevant articles and documents

Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes

The ever-growing prevalence of Type-2 diabetes in the world has an urgent need for multiple orally effective agents that can regulate glucose homeostasis. G-Protein coupled receptor 119 (GPR 119) agonists have demonstrated the glucose-dependent insulin secretion and showed beneficial effects on glycemic control in humans and/or relevant animal models. Herein, we describe our efforts towards identification of a potent and oral GPR 119 agonist 13c (ZY-G19), which showed in vitro potency in the cell-based assay and in vivo efficacy without exerting any significant signs of toxicity in relevant animal models.

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

INDOLYLPYRIMIDINES AS MODULATORS OF GPR119

The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions modulated by GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).

2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS

Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

PYRIMIDYL INDOLINE COMPOUND

It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:

BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a c

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO

New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein X1, X2, X3, X4, Y1

SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to certain substituted aryl and heteroaryl derivative of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complicati

Peptide compounds

The present invention relates to a compound of the formula (I)wherein R1 is benzofuranyl substituted by halogen, or styryl substituted by halogen; R2 is substituted hydroxy, substituted mercapto or substituted sulfonyl; and X is or pharmaceutically acceptable salts thereof. The compound (1) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases in human being and animals.